Coloplast Dividenden en inkoop

Dividend criteriumcontroles 3/6

Coloplast is een dividendbetalend bedrijf met een huidig rendement van 2.21% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

2.2%

Dividendrendement

0.06%

Terugkoop Rendement

Totaal aandeelhoudersrendement	2.3%
Toekomstig dividendrendement	2.7%
Dividendgroei	-0.3%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	88%

Recente updates van dividend en inkoop

Recent updates

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Het dividend per aandeel van 0QBO N is de afgelopen 10 jaar stabiel gebleven.

Groeiend dividend: De dividendbetalingen van 0QBO N zijn de afgelopen 10 jaar gestegen.

Dividendrendement versus markt

Coloplast Dividendrendement versus markt

Hoe verhoudt 0QBO N dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (0QBO N)	2.2%
Markt onderkant 25% (MX)	0%
Markt Top 25% (MX)	0%
Gemiddelde industrie (Medical Equipment)	0%
Analist prognose (0QBO N) (tot 3 jaar)	2.7%

Opmerkelijk dividend: Het dividend van 0QBO N ( 2.21% ) is niet noemenswaardig vergeleken met de onderste 25% van de dividendbetalers op de MX markt ( 2.58% ).

Hoog dividend: Het dividend 0QBO N ( 2.21% ) is laag vergeleken met de top 25% van dividendbetalers in de MX markt ( 7.03% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Bij de huidige payout ratio ( 88.5% ) worden de betalingen van 0QBO N gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Gezien de hoge cash payout ratio ( 116% ) worden de dividendbetalingen van 0QBO N niet goed gedekt door de kasstromen.

Coloplast Dividenden en inkoop

Dividend criteriumcontroles 3/6

Belangrijke informatie

Recente updates van dividend en inkoop

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Approves the Distribution of Year-End Dividend

Upcoming dividend of kr.14.00 per share

Upcoming Dividend of kr.13.00 Per Share

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend